论文部分内容阅读
目的:评估非那雄胺对中国人前列腺癌发病率及病理分级的影响。方法:将1029例BPH患者根据其药物治疗的方法分为非那雄胺组、α-受体阻滞剂组、联合用药组及对照组(未治疗组)。收集四组患者的穿刺病理资料,重新行Gleason评分。对四组患者前列腺癌发病率及前列腺癌病理分级的差异进行分析。结果:①前列腺癌总发病率为13.51%;应用非那雄胺组与未应用非那雄胺组比较差异有统计学意义(P<0.05),发病率相对下降40.63%(RR=0.59,95%CI:0.43～0.82)。②前列腺癌患者病理分级为中高级(Gleason≥7分)者占58.27%,应用非那雄胺组与未应用非那雄胺组比较差异有统计学意义(P<0.05),中高级分化前列腺癌相对增多33.96%(RR=1.34,95%CI:1.01～1.76)。结论:非那雄胺治疗BPH虽能降低前列腺癌的发病风险,但同时能使发生前列腺癌的病理级别增高。
Objective: To evaluate the effect of finasteride on the incidence and pathological grade of prostate cancer in Chinese. Methods: 1029 cases of BPH patients were divided into finasteride group, α-receptor blocker group, combination group and control group (untreated group) according to their drug treatment methods. Collect the puncture pathology data of four groups of patients and re-run the Gleason score. The differences between the four groups in the incidence of prostate cancer and the pathological grade of prostate cancer were analyzed. Results: ① The overall incidence of prostate cancer was 13.51%. The difference was statistically significant (P <0.05) between the finasteride group and the non-applied finasteride group, and the relative incidence decreased 40.63% (RR = 0.59, 95 % CI: 0.43 ~ 0.82). ②Patients with prostate cancer accounted for 58.27% of the patients with pathological grade of Gleason≥7 points, there was significant difference between those with and without finasteride (P <0.05) The relative increase of cancer was 33.96% (RR = 1.34, 95% CI: 1.01-1.76). Conclusion: Finasteride treatment of BPH can reduce the risk of prostate cancer, but can make the occurrence of prostate cancer pathological grade increased.